LCA Secures Additional $10.2 Million in Federal Research Funding!

Brings total to date to $58million secured by LCA via Department of Defense Lung Cancer Research Program

WASHINGTON, DC [Friday, December 16, 2011] -- Today, Lung Cancer Alliance (LCA) announced that its efforts to secure continued increases in federal research funding for lung cancer achieved another victory as an additional $10.2 million was included in the Department of Defense (DOD) Congressionally Directed Medical Research Program (CDMRP) which was part of the FY2012 budget compromise worked out late last night by the House and Senate.

This $1 trillion omnibus spending package includes nine appropriations measures which establish budgets for hundreds of programs across ten Cabinet agencies including the Department of Defense. The President is expected to sign the bill.

The $10.2 million in DOD research funding is in addition to $47.8 million secured to date by LCA since it first established the DOD lung cancer research pipeline three years ago which targets research for early detection with special emphasis on high risk military bringing the total appropriated to date to $58 million.

“We are proud to share that our advocacy work to date has secured $58 million for lung cancer research funding via this new program”, said Laurie Fenton-Ambrose, President and CEO of LCA. “Increasing the federal research pipeline for lung cancer has been -- and will continue to be -- LCA’s core mission.”

The omnibus spending package also includes a $30.7 billion increase in funding for research programs including lung cancer research within the National Institutes of Health – an increase strongly advocated for by LCA.

“Even in times of tight fiscal restraint,” continued Fenton-Ambrose, “we will continue these efforts for patients and survivors as well as our research community because it is essential and critical life-saving work. I thank our congressional leadership for continuing support for this program.”

Lung cancer is the leading cause of cancer death among men and women and every ethnic group and among our military who are at an increased risk in comparison to their civilian counterparts. Lung cancer has a 15% 5-year survival rate with the vast majority of cases found late stage. In addition, nearly 80% of those diagnosed with lung cancer today are former or non-smokers.

Military personnel have a higher exposure to lung cancer carcinogens and thus are more susceptible than the general public. The FY2012 language calls for continued research focus on screening and early disease management, especially among high risk military.

Lung Cancer Alliance is dedicated exclusively to providing patient support and advocacy for all those either living with or at risk for lung cancer. Lung Cancer remains committed to leading the movement to reverse decades of stigma and neglect by empowering patients, elevating awareness and changing health policy.